The Medical Letter on Drugs and Therapeutics
Influenza Vaccine 2008-2009
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce influenza complications.1 Changes this year include a vaccine with three new influenza antigens and expanded age criteria to include all children 6 months to 18 years of age. An upcoming issue of The Medical Letter will review drugs for prophylaxis and treatment of influenza.

VACCINE COMPOSITION — Both the inactivated and live attenuated vaccines for 2008-2009 include three new influenza antigens. The influenza A antigens are A/Brisbane/59/2007 (H1N1)-like and A/Brisbane/10/2007 (H3N2)-like. The influenza B antigen is B/Florida/4/2006-like. The influenza A-H3N2 and influenza B strains are currently in use for the Southern Hemisphere’s 2008 season vaccine.2

RECOMMENDATIONS — The US Advisory Committee on ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Influenza Vaccine 2008-2009
Article code: 1296a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian